Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Dec;44(12):3428-31.
doi: 10.1128/AAC.44.12.3428-3431.2000.

Bactericidal activities of antibiotics against intracellular Francisella tularensis

Affiliations

Bactericidal activities of antibiotics against intracellular Francisella tularensis

M Maurin et al. Antimicrob Agents Chemother. 2000 Dec.

Abstract

MICs of many antibiotics for Francisella tularensis are low in axenic medium, whereas only aminoglycosides, tetracyclines, and fluoroquinolones are useful in treating tularemic patients. In an in vitro cell system, only these antibiotics, rifampin, and telithromycin were bactericidal against intracellular F. tularensis. These results correlate better with clinical data than MIC data do.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Activities of antibiotics against intracellular F. tularensis. (A) Penicillin G (10 μg/ml), amoxicillin (10 μg/ml), ceftriaxone (10 and 100 μg/ml), streptomycin (10 μg/ml), gentamicin (3 and 10 μg/ml), and amikacin (10 μg/ml). (B) Doxycycline (4 μg/ml), thiamphenicol (4 μg/ml), rifampin (4 μg/ml), trimethoprim-sulfamethoxazole (10 and 50 μg/ml, respectively), erythromycin (4 μg/ml), clarithromycin (4 μg/ml), telithromycin (4 μg/ml), ofloxacin (1 μg/ml), and ciprofloxacin (1 μg/ml). I/Io, ratio of the viable bacterial titers (CFU per milliliter), after 24, 48, or 72 h of incubation of cultures in the presence of the various antibiotics tested to the primary F. tularensis inoculation dose. Data correspond to a single experiment performed in triplicate. All data points with at least a 1-log decrease were statistically significantly different from controls (P < 0.001).

Similar articles

Cited by

References

    1. Aubry-Damon H, Soussy C-J, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1998;42:2590–2594. - PMC - PubMed
    1. Baker C N, Hollis D G, Thornsberry C. Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J Clin Microbiol. 1985;22:212–215. - PMC - PubMed
    1. Bhatnagar N, Getachew E, Straley S, Williams J, Meltzer M, Fortier A. Reduced virulence of rifampicin-resistant mutants of Francisella tularensis. J Infect Dis. 1994;170:841–847. - PubMed
    1. Cross J T, Jacobs R F. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis. 1993;17:976–980. - PubMed
    1. Cross J T J, Schutze G E, Jacobs R F. Treatment of tularemia with gentamicin in pediatric patients. Pediatr Infect Dis J. 1995;14:151–152. - PubMed

Substances